Summarized by Masters of Longevity from Nature - Main.
A patient-focused news article about an experimental RNA-based antisense therapy trial for a rare motor-neuron disorder, highlighting early clinical observations and implications.
Key Takeaways
- A patient with CHCHD10-linked motor neuron disease received intrathecal antisense oligonucleotide doses between April 2024 and April 2025.
- Blood neurofilament light chain levels fell into the normal reference range one year after the first dose.
- Motor, breathing, and neurological function scores improved or remained stable and no serious adverse events were reported.
